Stock AnalizMckesson Corp. MCK
Other Pharmaceuticals · data as of November 13, 2026
Mckesson Corp. (MCK) is a healthcare company listed in the US with a market value of about $127.3B. In the twelve months to September 30, 2026 it had revenue of $418.8B and net income of $4.7B, a net margin of 1.1%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is shareholder returns (5/5); the weakest is value (1/5).
Key numbers: a P/E of 28.4, a price to free cash flow of 17.9, 5-year revenue growth of 11% a year, a 5-year average ROIC of 59%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 4% below the current price.
Score: 3.0 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.8B | $403.4B | $359.1B | $309.0B | $276.7B | $264.0B | $238.2B | $231.1B | $214.3B | $208.4B | $198.5B |
| Net income | $4.7B | $4.8B | $3.3B | $3.0B | $3.6B | $1.1B | -$4.5B | $900M | $34M | $67M | $5.1B |
| Free cash flow | $7.1B | $5.7B | $5.5B | $3.9B | $4.8B | $4.0B | $4.1B | $4.0B | $3.6B | $3.9B | $4.3B |
| EPS (diluted) | $38.83 | $38.38 | $25.72 | $22.39 | $25.03 | $7.23 | $-28.26 | $4.95 | $0.17 | $0.32 | $22.73 |
| Net margin | 1.1% | 1.2% | 0.9% | 1.0% | 1.3% | 0.4% | -1.9% | 0.4% | 0.0% | 0.0% | 2.5% |
| ROIC | — | 79.3% | 66.4% | 60.2% | 64.8% | 25.9% | -46.3% | 16.9% | 3.9% | 3.4% | 28.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $1144.29, 4% above the current price; targets range from $965.00 to $1260.00; the consensus rating is “Buy”; expected EPS is $45.75 for the fiscal year ending March 31, 2027.
Frequently asked questions
What is Mckesson’s P/E ratio?
About 28.4, based on the last twelve months of diluted earnings per share (forward P/E about 21.8).
Is Mckesson stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 4% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Mckesson pay a dividend?
Yes. The dividend yield is about 0.35%, and it has paid dividends for 10 years in our data.
Is Mckesson a good stock to buy?
We do not give buy or sell advice. Mckesson scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.